X4 Pharmaceuticals, Inc.
XFOR
$3.35
$0.1655.19%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -25.74M | 282.00K | -39.82M | -36.70M | 90.83M |
| Total Depreciation and Amortization | 355.00K | 476.00K | 273.00K | 267.00K | 194.00K |
| Total Amortization of Deferred Charges | 212.00K | 225.00K | 201.00K | 194.00K | 207.00K |
| Total Other Non-Cash Items | -519.00K | -10.07M | 5.16M | 3.86M | -122.56M |
| Change in Net Operating Assets | -4.21M | -3.28M | 1.20M | -1.66M | 1.05M |
| Cash from Operations | -29.90M | -12.37M | -33.00M | -34.03M | -30.28M |
| Capital Expenditure | -- | -- | -41.00K | -92.00K | -134.00K |
| Sale of Property, Plant, and Equipment | -- | -- | 0.00 | 0.00 | 105.00M |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 23.11M | -3.14M | -8.58M | -15.84M | -8.00M |
| Cash from Investing | 23.11M | -3.14M | -8.62M | -15.93M | 96.86M |
| Total Debt Issued | -- | -- | 0.00 | 0.00 | 20.00M |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 5.63M | -- | 135.00K | 0.00 | 159.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 5.63M | -- | 135.00K | 0.00 | 20.16M |
| Foreign Exchange rate Adjustments | 139.00K | 72.00K | -244.00K | 165.00K | -18.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1.02M | -15.43M | -41.73M | -49.80M | 86.73M |